Sollis Therapeutics, Inc.
https://www.sollistx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sollis Therapeutics, Inc.
Breaking The Pain Market’s Addiction To Opioids
The recent success of Vertex in acute pain merely highlights the agonizingly slow process elsewhere, particularly in chronic pain indications.
Venture Funding Deals: Four $100m-Plus Rounds, Including Allogene's $300m
April had four VC rounds of $100m or more, including Allogene's $300m to develop CAR-T therapies licensed from Pfizer. Innovent Biologics raised $150m, BenevolentAI brought in $115m and Constellation garnered $100m last month.
Finance Watch: Former Alexion Execs Raise $37m To Launch Rare-Disease Focused RallyBio
Private Company Edition: Martin Mackay and two other former Alexion executives co-founded the rare disease start-up in January with a $37m Series A to kick things off. Also, Innovent raises $150m in venture cash, Tmunity adds $35m and Third Rock launches Cedilla.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice